NeuroMetrix Adds to its Scientific Advisory Board

NeuroMetrix Inc. has appointed its first Asian-Pacific board member.

The company recently announced that Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Nakamura is a professor in the Division of Diabetes, Department of Internal Medicine, Diabetes Center at the Aichi Medical University School of Medicine in Nagakute, Japan.

Nakamura has focused on diabetes throughout his career. His particular emphasis has been on the vascular and cardio-vascular complications of diabetes as well as on diabetic neuropathy. Nakamura has published widely, has been the principal investigator on  various clinical studies, and serves on the editorial boards of the Journal of Diabetes Investigation, Diabetology International, and Experimental Diabetes Research. He is a member of the American Diabetes Association, International Diabetes Federation, Japan Diabetes Society and other professional societies, often serving as a board member or member of the scientific committee. Nakamura is considered a leader in the field of diabetes research and treatment, NeuroMetrix claims.

“We are honored that Dr. Nakamura has joined our Scientific Advisory Board,” NeuroMetrix President/CEO Shai N. Gozani, M.D., Ph.D., said. “This group of international leaders in the detection, management and treatment of the neurological complications of diabetes plays a key role in our product development efforts. Dr. Nakamura’s position in the Japan medical profession and understanding of local medical practice will be a valuable near-term source of advice and guidance as we move toward the launch of NC-stat DPNCheck in the Japanese market during 2014.”

Nakamura joins NeuroMetrix Scientific Board members David. G. Armstrong, D.P.M., M.D., Ph.D., a professor of surgery at the University of Arizona and co-founder of the Southern Arizona Limb Salvage Alliance; Andrew J.M. Boulton, M.R.C.P., M.D., F.R.C.P., a professor of Medicine at the University of Manchester and Consulting Physician, Manchester Royal Infirmary, Manchester, United Kingdom and professor of Medicine, Diabetes Research Institute at the University of Miami (Florida); Bruce A. Perkins, M.D., M.P.H., F.R.C.P., an assistant professor at the University of Toronto, Canada; Soloman Tesfaye, M.B., Ch.B., M.D., F.R.C.P., a consultant physician/endocrinologist at the Royal Hallamshire Hospital, Sheffield, United Kingdom, and honorary professor of Diabetic Medicine at the University of Sheffield; Aaron I. Vinik, M.D., Ph.D., F.C.P., F.A.C.P. (F.R.C.P.), a professor of Medicine, Pathology and Neurobiology and director of Research at the Neuroendocrine Unit of the Strelitz Diabetes Center for Endocrine and Metabolic Disorders, Eastern Virginia Medical School in Norfolk, Va.; and Dan Ziegler, M.D., F.R.C.P.E., a professor of Medicine at the Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, and the Department of Metabolic Diseases, University Hospital in Dusseldorf, Germany.

NeuroMetrix is a Waltham, Mass.-based developer of home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The company presently is focused on diabetic neuropathies, which affect more than 50 percent of diabetics. 

The company markets the Sensus Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck device, a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy.